1.
Clin Investig Arterioscler
; 35(2): 88-90, 2023.
Artigo
em Inglês, Espanhol
| MEDLINE
| ID: mdl-36641361
RESUMO
Anti-PCSK9 monoclonal antibodies have reduced the risk of cardiovascular events in patients with atheroesclerosis cardiovascular disease. However, its use has not been described in hyperlipidemia associated with lorlatinib, a third-generation ALK tyrosin kinasa inhibitor approved as treatment for ALK-positive non-small cell lung cancer.